全文获取类型
收费全文 | 452篇 |
免费 | 48篇 |
国内免费 | 18篇 |
专业分类
耳鼻咽喉 | 2篇 |
儿科学 | 14篇 |
妇产科学 | 37篇 |
基础医学 | 64篇 |
口腔科学 | 11篇 |
临床医学 | 37篇 |
内科学 | 136篇 |
皮肤病学 | 6篇 |
神经病学 | 11篇 |
特种医学 | 77篇 |
外科学 | 47篇 |
综合类 | 5篇 |
预防医学 | 28篇 |
眼科学 | 2篇 |
药学 | 10篇 |
中国医学 | 2篇 |
肿瘤学 | 29篇 |
出版年
2023年 | 1篇 |
2021年 | 3篇 |
2020年 | 8篇 |
2019年 | 5篇 |
2018年 | 13篇 |
2017年 | 8篇 |
2016年 | 9篇 |
2015年 | 8篇 |
2014年 | 11篇 |
2013年 | 19篇 |
2012年 | 8篇 |
2011年 | 19篇 |
2010年 | 27篇 |
2009年 | 22篇 |
2008年 | 13篇 |
2007年 | 33篇 |
2006年 | 14篇 |
2005年 | 13篇 |
2004年 | 8篇 |
2003年 | 16篇 |
2002年 | 6篇 |
2001年 | 8篇 |
2000年 | 6篇 |
1999年 | 8篇 |
1998年 | 15篇 |
1997年 | 15篇 |
1996年 | 14篇 |
1995年 | 13篇 |
1994年 | 14篇 |
1993年 | 18篇 |
1992年 | 5篇 |
1991年 | 3篇 |
1990年 | 10篇 |
1989年 | 20篇 |
1988年 | 20篇 |
1987年 | 18篇 |
1986年 | 9篇 |
1985年 | 10篇 |
1984年 | 5篇 |
1983年 | 11篇 |
1982年 | 5篇 |
1981年 | 4篇 |
1980年 | 6篇 |
1979年 | 2篇 |
1978年 | 1篇 |
1977年 | 7篇 |
1976年 | 5篇 |
1975年 | 2篇 |
排序方式: 共有518条查询结果,搜索用时 140 毫秒
511.
512.
513.
514.
Chen KW Wang WY Liang WM Twu CW Chao JY Liang KL Wu CT Jiang RS Shih YT Lin JC 《Oral oncology》2011,47(12):1171-1175
We investigated the effect of retropharyngeal nodal volumes (RNV) on distant metastasis in patients with advanced nasopharyngeal carcinoma (NPC). From February 2000 to June 2006, a total of 181 patients with biopsy-proven NPC, no distant metastasis, and available pre-treatment magnetic resonance imaging (MRI) were retrospectively reviewed. Most of the patients (95.6%) had stage III/IV diseases. The contour of retropharyngeal nodes ≥5mm was delineated on the axial slides of pre-treatment T2-weighted MRI without contrast enhancement. The RNV was calculated by the Eclipse? treatment planning software. The primary end-points were subsequent distant failure rates and distant metastasis failure-free survival (DMFFS). The pre-treatment RNV in patients who developed distant failure was higher than in those without distant failure (P=0.0536). The distant failure rates between the patients with RNV > and ≤4.68cm(3) were 33.3% and 16.0%, respectively (P=0.0112). The rates of 7-year DMFFS in patients with RNV > and ≤4.68cm(3) were 66.4% and 83.5%, respectively (P=0.0043). Multivariate Cox analysis showed N-stage (P<0.001), gender (P=0.026), and RNV (P=0.088) were important predictors for DMFFS. We conclude that the RNV measured by MRI is a potential predictor of distant metastasis in patients with advanced NPC. 相似文献
515.
516.
Taiwanese Gynecologic Oncology Group Chou HH Wang KL Chen CA Wei LH Lai CH Hsieh CY Yang YC Twu NF Chang TC Yen MS 《Gynecologic oncology》2006,101(3):423-428
OBJECTIVES: To evaluate the efficacy and safety of a distearoylphosphatidylcholine pegylated liposomal doxorubicin, Lipo-Dox, in platinum-resistant or refractory epithelial ovarian cancer. METHODS: A multicenter phase II trial enrolled women with platinum-resistant or refractory epithelial ovarian carcinoma and na?ve to anthracycline. Eligible patients had either measurable tumor(s) or elevated serum CA 125 titer. Lipodox was initiated with a dose of 45 mg/m2 at a 4-week interval with subsequent escalation or reduction. A total of six cycles were scheduled. RESULTS: 29 patients, 20 with platinum-resistant and 9 with platinum refractory tumors, were enrolled. Lipo-Dox was given for an average of 4.6 cycles per patient with a total of 134 cycles. Among the 26 evaluable patients, one achieved CR, 5 PR and 9 SD. The overall response rate was 23.1% (95% CI, 6.8%-39.3%) with a median response duration of 11.6 weeks. 5 of the 6 responses were in patients with resistant disease. The median progression-free duration in the SD patients was 25.7 weeks. With a median follow-up of 13.8 months, the median progression-free and median overall survivals in the 26 patients were 5.4 months and 13.8 months, respectively. Hand-foot skin reaction occurred in 4.5% and skin pigmentation in 11.2% of all treatment cycles, all were Grade 1/2. Nausea and vomiting occurred in 14.2%, while anemia, leukopenia and thrombocytopenia occurred in 20.9%, 32.8% and 9% of cycle, respectively, and were mostly Grade 1 or 2. CONCLUSION: Lipo-Dox, the third liposome encapsulated doxorubicin, at 45 mg/m2 every 4 weeks, is effective against recurrent, platinum-resistant epithelial ovarian cancers. 相似文献
517.
518.
Taigang He Paul Kirk David N Firmin Wynnie M Lam Winnie CW Chu Wing-Yan Au Godfrey CF Chan Ru San Tan Ivy Ng Selen Biceroglu Yesim Aydinok Mark A Fogel Alan R Cohen Dudley J Pennell 《Journal of cardiovascular magnetic resonance》2008,10(1):11